盘龙药业(002864) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 was ¥216,214,281.13, a decrease of 17.62% compared to the same period last year[4] - Net profit attributable to shareholders was ¥29,849,044.15, down 9.82% year-on-year, while the net profit excluding non-recurring items was ¥34,257,799.52, an increase of 4.98%[4] - Total operating revenue for Q3 2023 reached ¥716,232,654.94, an increase of 3.6% compared to ¥693,447,695.00 in Q3 2022[20] - Net profit for Q3 2023 was ¥84,515,018.33, compared to ¥79,940,900.98 in the same period last year, representing a growth of 5.5%[21] - The total comprehensive income for Q3 2023 was ¥84,515,018.33, compared to ¥79,940,900.98 in the same period last year, indicating an increase of about 5.5%[22] Assets and Liabilities - The total assets at the end of Q3 2023 reached ¥2,096,053,514.17, reflecting an increase of 8.56% from the end of the previous year[4] - Total current assets as of Q3 2023 were ¥1,641,807,228.30, compared to ¥1,481,949,548.22 at the end of Q3 2022, indicating a growth of 10.8%[18] - Total liabilities decreased to ¥569,841,854.62 from ¥983,183,297.68, a reduction of 42.0% year-over-year[18] - The company's total assets increased to ¥2,096,053,514.17, up from ¥1,930,786,964.46, reflecting an increase of 8.6%[18] - The equity attributable to shareholders rose to ¥1,524,399,980.73, compared to ¥929,650,723.07, an increase of 64.0%[18] Cash Flow - Cash flow from operating activities was ¥82,258,635.90, down 28.37% from the previous year, primarily due to increased expenditure[9] - Cash inflow from operating activities totaled ¥788,237,385.15, up from ¥763,137,296.85 in the previous year, reflecting a growth of approximately 3.3%[24] - The net cash flow from operating activities decreased to ¥82,258,635.90 from ¥114,832,020.89, a decline of about 28.4% year-over-year[24] - Cash and cash equivalents stood at ¥1,096,674,533.70, compared to ¥823,443,964.90, representing a growth of 33.1%[18] - The company reported cash inflow from financing activities of ¥428,744,887.30, slightly down from ¥445,510,975.56 in the previous year[25] Shareholder Information - The number of common shareholders at the end of the reporting period was 26,180[11] - The largest shareholder, Xie Xiaolin, holds 38.37% of the shares, totaling 37,189,932 shares[11] - The total number of shares held by the top 10 unrestricted shareholders includes 9,297,483 shares held by Xie Xiaolin[11] - The company has not disclosed any related party relationships among the top shareholders[11] Research and Development - Research and development expenses increased by 71.89% to ¥15,741,181.57, indicating a significant rise in investment in R&D[9] - Research and development expenses increased significantly to ¥15,741,181.57, up from ¥9,157,723.10, marking a rise of 72.5% year-over-year[21] Capital and Investments - The company’s capital reserve increased by 215.87% to ¥819,459,655.50, mainly due to the conversion of convertible bonds and stock issuance[9] - The company received government subsidies amounting to ¥3,967,754.31 during the reporting period, contributing to its financial performance[5] - The company reported a significant increase in other income, which rose by 155.09% to ¥7,292,558.12, attributed to increased government subsidies related to daily operations[9] - The total amount raised from the issuance of shares to specific investors was RMB 301,999,974.60, with a net amount of RMB 294,836,292.23 after deducting issuance costs[13] - The newly issued shares amounted to 9,352,740, increasing the total share capital to 106,280,960 shares[14] Corporate Actions - The company transferred 51% of its stake in Shaanxi Bohua Pharmaceutical Co., Ltd. for a transaction price of RMB 10.2 million[14] - The company established a wholly-owned subsidiary, Shaanxi Panlong Valley Cultural Tourism Health Co., Ltd., with a registered capital of RMB 100 million[14] - The company received approval from the China Securities Regulatory Commission for the issuance of A-shares to specific investors on August 2, 2023[12] Earnings Per Share - The company reported a basic earnings per share of ¥0.3300, a decrease of 15.38% compared to the same period last year[4] - The company’s basic earnings per share remained stable at ¥0.9100, while diluted earnings per share increased to ¥0.9100 from ¥0.8812[22]